

Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia

Richard Vollenberg,¹ Rabie Jouni,² Peter A. A. Norris,³ Monika Burg-Roderfeld,⁴ Nina Cooper,¹ Mathias J. Rummel,⁵ Gregor Bein,¹ Irene Marini,² Behnaz Bayat,¹ Richard Burack,⁶ Alan H. Lazarus,³ Tamam Bakchoul^{2*} and Ulrich J. Sachs^{1,7*}

**TB and UJS contributed equally to this work*

¹Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany; ²Center for Clinical Transfusion Medicine, Medical Faculty of Tübingen, Eberhard Karls University, Tübingen, Germany; ³The Canadian Blood Services & The Keenan Research Centre of St. Michael's Hospital, Toronto, ON, Canada; ⁴Faculty for Chemistry and Biology, Fresenius University of Applied Sciences, Idstein, Germany; ⁵IVth Department of Internal Medicine (Hematology/Oncology), Justus Liebig University, Giessen, Germany; ⁶Department of Pathology and Laboratory Medicine, University of Rochester, NY, USA and ⁷Center for Transfusion Medicine and Hemotherapy and Hemostasis Center, University Hospital Giessen and Marburg, Marburg, Germany


©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.211086

Received: November 5, 2018.

Accepted: March 20, 2019.

Pre-published: March 28, 2019.

Correspondence: *ULRICH J. SACHS* - ulrich.sachs@med.uni-giessen.de



Supplemental figure 1. Schematic representation of the tests performed in this study.